News | November 24, 2010

Survey Finds Cardiologists View Crestor as Comparable to Lipitor

November 24, 2010 – Cardiologists and primary care physicians now perceive AstraZeneca's Crestor as comparable to Pfizer’s Lipitor in treating and reducing mortality in dyslipidemia patients, according to a survey by Decision Resources.

This finding has changed from Decision Resources' 2009 analysis in which surveyed cardiologists viewed Lipitor as significantly better.

According to Treatment Algorithms in Dyslipidemia, patient share for Crestor has increased to 10.6 percent in the first line, 17.5 percent in second line and is the most-prescribed drug in the third line with 22.9 percent share. The results of the JUPITER trial, which were reported in November 2008, have improved physician perception of Crestor's mortality benefits. Additionally, other drivers include advantages in efficacy as well as fallout from Merck's Zetia and Vytorin, which have received negative publicity from two clinical trials.

"Crestor has overtaken Lipitor in many cases as the second-line treatment of choice, often following first-line simvastatin," said Taskin Ahmed, an analyst at Decision Resources. "However, this trend may be reversed once generic Lipitor becomes available. Despite physicians acknowledging some advantages of Crestor over Lipitor, cost is a tipping point for many physicians who will use less of the higher-priced Crestor. In response, AstraZeneca will need to do more to convince physicians about the benefits of Crestor ahead of Lipitor's patent loss. The company may get the ammunition it needs if results are positive from the head-to-head Crestor versus Lipitor SATURN trial on atherosclerosis, which will report next year."

For more information: www.decisionresources.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Study Discovers Anticoagulant Drugs Are Being Prescribed Against Safety Advice
News | Antiplatelet and Anticoagulation Therapies| July 25, 2017
July 25, 2017 — A study by researchers at the University of Birmingham has shown that general practitioners (GPs) are
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Sex-Specific Cardiovascular Drug Dosages Needed to Reduce Adverse Reactions in Women
News | Womens Healthcare| July 07, 2017
Sex-specific cardiovascular drug dosages are needed to reduce adverse reactions in women, according to a position paper...
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension| July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
FDA Grants Priority Review of Xarelto sNDA for 10 mg Dose
News | Antiplatelet and Anticoagulation Therapies| June 29, 2017
Janssen Research & Development LLC announced the U.S. Food and Drug Administration (FDA) accepted for Priority...
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Cost comparison between NOACs, novel oral anticoagulants
News | Antiplatelet and Anticoagulation Therapies| May 31, 2017
May 31, 2017 – The results from the first real-world, matched head-to-head study comparing all-cause healthcare costs
Data was positive from the Watchman Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry
News | Atrial Fibrillation| May 30, 2017
May 30, 2017 — Data was positive for safety and efficacy rates of the Watchman Left Atrial Appendage Closure (LAAC) D
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Overlay Init